Advanced search
Publication Cover
Acta Cardiologica Volume 65, 2010 - Issue 3
Submit an article Journal homepage
3
Views
1
CrossRef citations to date
0
Altmetric
Articles

Insulin resistance and heart injury in rats with insulin resistance or type 2 diabetes mellitus

Zhong-Hua YangDept. of Geriatrics, the West China Hospital of Sichuan University, Chengdu, Sichuan, China.Correspondence[email protected]
, MD &
Xiao-Dong PengState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, China.
, PhD
Pages 329-335 | Received 13 Jul 2009, Accepted 12 Feb 2010, Published online: 23 May 2017

References

  • Codinach Huix P, Freixa Pamias R. Diabetic cardiomyo-pathy: concept, heart function, and pathogenesis. An Med Interna 2002; 19: 313–20 [in Spanish].
  • Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 2004; 25: 543–67.
  • Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972; 30: 595–602.
  • Hamby RI, Zoneraich S, Sherman L. Diabetic cardiomyo-pathy. JAMA 1974; 229: 1749–54.
  • Francis GS. Diabetic cardiomyopathy: fact or fiction? Heart 2001; 85: 247–8.
  • Konduracka E, Gackowski A, Rostoff P, Galicka-Latala D, Frasik W, Piwowarska W Diabetes-specific cardiomyopathy in type 1 diabetes mellitus: no evidence for its occurrence in the era of intensive insulin therapy. Eur Heart J 2007; 28: 2465–71.
  • An D, Rodrigues B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2006; 291: H1489–506.
  • Feuvray D. Diabetic cardiomyopathy. Arch Mal Coeur Vaiss 2004; 97: 261–5.
  • Neely JR, Rovetto MJ, Oram JF. Myocardial utilization of carbohydrate and lipids. Frog Cardiovasc Dis 1972; 15: 289–329.
  • Lopaschuk GD, Spafford M. Response of isolated working hearts to fatty acids and carnitine palmitoyltransferase I inhibition during reduction of coronary flow in acutely and chronically diabetic rats. Circ Res 1989; 65: 378–87.
  • Belke DD, Larsen TS, Gibbs EM, Severson DL. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol Endocrinol Metab 2000; 279: E1104–13.
  • Chang-Quan H, Bi-Rong D, Qian X, Ping H, Qun-Fang D, Zhen-Chan L, Xiao-Dong P. Renal injury, abnormal vitamin D metabolism and bone homeostasis in aged rats with insulin resistance or type 2 diabetes mellitus. J Investig Med 2008; 56: 872–7.
  • Chang-Quan H, Bi-Rong D, Ping H, Zhen-Chan L, Xiao-Dong P Insulin resistance, renal injury, renal 1-alpha hydroxy-lase, and bone homeostasis in aged obese rats. Arch Med Res 2008; 39: 380–7.
  • Blaedel WJ, Uhl JM. Nature of materials in serum that inter-fere in the glucose oxidase-peroxidase-0-dianisidine method for glucose, and their mode of action. Clin Chem 1975; 21: 119–24.
  • Straczkowski M, Stepieri, Kowalska I, Kinalska I. Compar-ison of simple indices of insulin sensitivity using the eug-lycemic hyperinsulinemic clamp technique. Med Sci Monit 2004; 10: CR480-4.
  • Woessner JF Jr. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 1961; 93: 440–7.
  • Zhao XY, Hu SJ, Li J, Mou Y, Chen BP, Xia Q. Decreased cardiac sarcoplasmic reticulum Ca2 + -ATPase activity con-tributes to cardiac dysfunction in streptozotocin-induced diabetic rats. J Physiol Biochem 2006; 62: 1–8.
  • Choi KM, Zhong Y, Hoit BD, Grupp IL, Hahn H, Dilly KW, Guatimosim S, Lederer WJ, Matlib MA. Defective intracellular Ca(2 +) signaling contributes to cardiomyopa-thy in Type 1 diabetic rats. Am J Physiol Heart Circ Physiol 2002; 283: H1398–408.
  • Pereira L, Matthes J, Schuster I, Valdivia HH, Herzig S, Richard S, Gómez AM. Mechanisms of [Ca2 +]i transient decrease in cardiomyopathy of db/db type 2 diabetic mice. Diabetes 2006; 55: 608–15.
  • Belke DD, Swanson EA, Dillmann WH. Decreased sarco-plasmic reticulum activity and contractility in diabetic db/db mouse heart. Diabetes 2004; 53: 3201–8.
  • Barrans JD, Allen PD, Stamatiou D, Dzau VJ, Liew CC. Global gene expression profiling of end-stage dilated car-diomyopathy using a human cardiovascular-based cDNA microarray. Am J Pathol 2002: 160: 2035–43.
  • Cai L, Wang Y, Thou G, Chen T, Song Y, Li X, Kang YJ. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J Am Coll Cardiol 2006; 48: 1688–97.
  • Shen X, Zheng S, Metreveli NS, Epstein PN. Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes 2006; 55: 798–805.
  • Li SY, Yang X, Ceylan-Isik AF, Du M, Sreejayan N, Ren J. Cardiac contractile dysfunction in Lep/Lep obesity is accom-panied by NADPH oxidase activation, oxidative modifica-tion of sarco(endo)plasmic reticulum Ca2 +-ATPase and myosin heavy chain isozyme switch. Diabetologia 2006; 49: 1434–46.
  • Wohaieb SA, Godin DV. Alterations in free radical tissue-defense mechanisms in streptozocin-induced diabetes in rat. Effects of insulin treatment. Diabetes 1987; 36: 1014–8.
  • Volkovová K, Chorváthová V, Jurcovicová M, Koszeghyová L, Bobek P. Antioxidative state of the myocardium and kid-neys in acute diabetic rats. Physiol Res 1993; 42: 251–5.
  • Aliciguzel Y, Ozen I, Aslan M, Karayalcin U. Activities of xanthine oxidoreductase and antioxidant enzymes in differ-ent tissues of diabetic rats. J Lab Clin Med 2003; 142: 172–7.
  • Ye G, Metreveli NS, Donthi RV, Xia S, Xu M, Carlson EC, Epstein PN. Catalase protects cardiomyocyte function in models of type 1 and type 2 diabetes. Diabetes 2004; 53: 1336–43.
  • Cai L, Li W, Wang G, Guo L, Jiang Y, Kang YJ. Hyper-glycemia-induced apoptosis in mouse myocardium: mito-chondrial cytochrome C-mediated caspase-3 activation path-way. Diabetes 2002; 51: 1938–48.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Novo Nordisk – Driving change to defeat serious chronic diseases.
A bold vision to stop cardiovascular disease from being a leading cause of death.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.